Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab and Niraparib in Relapsed Ovarian Cancer
NCT05126342Phase 2Withdrawn
- Sponsor
- AGO Research
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of dostarlimab, niraparib in recurrent ovarian cancer (ROC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Research. Planned start Nov 2023; status: withdrawn.
02
Drugs
dostarlimabniraparib
03
Conditions
recurrent ovarian cancer (ROC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05126342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126342.